|
|
|||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Tuberculosis Epidemiologic Studies Consortium (TBESC)Task Order 2: Prospective Evaluation of immunogenetic and immunologic markers for susceptibility to M. tuberculosis infection and progression from M. tuberculosis infection to active TBTask order 2 assesses human immunologic and genetic factors that may predispose persons to getting infected with M. tuberculosis if exposed and developing active TB disease if infected. In an effort to identify risk factors for Mycobacterium tuberculosis transmission from cases to contacts in various settings, the study also seeks to determine the characteristics of adults with active culture-positive pulmonary tuberculosis, their contacts, the environment in which contact occurred, and the organisms associated with defined rates of M. tuberculosis transmission. SitesAmerican Lung Association of Metropolitan Chicago, Arkansas Department of Health, University of British Columbia, Charles Felton National Tuberculosis Center, Denver Department of Health and Hospitals, Emory University, University of Manitoba, Maryland Department of Health and Mental Hygiene, Mississippi State Department of Health, New Jersey Department of Health, and Tennessee Department of Health/Vanderbilt University. Study Objectives
Study designIncident cases of culture-positive pulmonary tuberculosis among persons 15 years of age and older reported from April 1, 1999 - April 1, 2000 (enrollment went through December 31, 2006) and all identified contacts of these cases were included. The prospective study involved case interviews, contact tuberculin skin test (TST) screening and interviews, laboratory record review, and data abstraction from medical records. Infected contacts were offered preventive therapy according to CDC recommendations. All identified contacts will be cross-matched with state TB registries at the end of study enrollment, one year after the end of enrollment, and two years after the end of enrollment to determine the proportion of patients who developed active TB subsequent to initial investigation. HIV testing was offered to all cases and contacts at the time of enrollment so that HIV status could be factored into decisions regarding anti-tuberculous therapy for cases and preventive therapy for contacts, and in order to stratify by HIV status when evaluating risk factors for TB infection and progression to TB disease among contacts. All cases and contacts will also be cross-matched to state HARS registries. Study progressThe current enrollment is 1986 genetic contacts, 2250 immunologic contacts, 970 epidemiologic cases, and 7000 epidemiologic contacts. Assays for 26 out of 33 candidate genes have been developed at CDC and assays are under development for the remaining 7 candidate genes. Data entry for 910 of the 970 epidemiologic cases and 6500 of the 7000 contacts has been completed. Data cleaning is expected to begin soon and when completed, data analysis will begin. Four writing teams (contact investigation outcomes, epidemiologic risk factors, immunologic markers, and genetic determinants) have been formed, with more than 15 manuscripts planned. Last Modified: 07/25/2007 Last Reviewed: 05/18/2008 |
|
|
If you would like to order any of the DTBE publications please visit the online order form. You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat™ Reader. If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available. Division of Tuberculosis Elimination
Centers for Disease Control & Prevention |